Avid Bioservices Inc (CDMO)

[north40000]

Your last paragraph, some additions to keep in mind:

1) PFM has an ongoing collaboration with MSKCC for several years; PPHM likewise.

2) PFM along with Vanderbilt-Ingram CC, Providence CC were authors with PPHM’s Dr. N. Kallinterris of the post-Sunrise prognostic and/or predictive biomarkers poster presented at AACR 2017 this past April. Even then, the data supported...”[planning of] Clinical trials combining bavituximab and immunotherapy agents such as checkpoint inhibitors...”[SUMMARY].

3) Drs Kallinterris, Kleen(Epiontis, now PFM’s VP of Immune Monitoring) were co-authors with others of the last biomarkers poster from Sunrise presented at SITC this past November; CJG has archived an image of that poster in stickies above.

It will be very interesting, IMO, to see and hear what our new BOD decides to do with all known clinical and biomarkers data extracted from Sunrise. Would one or more seamless clinical trials for multiple indications be in the offing, per licensing of PFM and MSKCC?